Global Information
회사소개 | 문의

심근염 : 파이프라인 리뷰

Myocarditis - Pipeline Review, H2 2018

리서치사 Global Markets Direct
발행일 2018년 08월 상품 코드 302498
페이지 정보 영문 39 Pages
가격
US $ 2,000 ₩ 2,296,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,592,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 6,888,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


심근염 : 파이프라인 리뷰 Myocarditis - Pipeline Review, H2 2018
발행일: 2018년 08월 페이지 정보 : 영문 39 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

한글목차

심근염이란 심장 근육의 염증으로, 보통 심장에 도달한 바이러스·세균·진균류 감염에 의해 발병하는 낮은 빈도의 질환입니다. 주요 증상으로 흉통 및 심박수 급증/이상, 휴식시 또는 신체 활동시 호흡곤란, 다리·발목·발의 붓기를 수반하는 체액류, 권태감 등이 있습니다. 주요 치료법으로는 항생물질 및 항염증제에 의한 종창 해소, 이뇨제에 의한 과잉 체액 배출 등을 들 수 있습니다.

세계 각국의 심근염(Myocarditis) 치료용 파이프라인 제품 개발 상황에 대해 분석했으며, 제품 개발 및 출시 최신 동향, 임상시험 단계별 제품 리스트, 주요 기업 개요, 주요 치료제 개요, 최신 업계 동향 등의 정보를 정리하여 전해드립니다.

목차

서론

  • 분석 범위

심근염 개요

치료제 개발

  • 심근염용 파이프라인 제품 : 개요
  • 심근염용 파이프라인 제품 : 비교 분석

각 기업에서 개발중인 심근염 치료제

대학/연구기관에서 연구중인 심근염 치료제

파이프라인 제품 개요

  • 초기 단계 제품

심근염 치료제 : 개발중인 제품 목록(기업별)

심근염 치료제 : 연구중인 제품 목록(대학/연구기관별)

심근염 치료제 개발에 참여하고 있는 기업

  • CEL-SCI Corporation
  • GlaxoSmithKline Plc

심근염 : 치료제 평가

  • 단독치료 제품(Monotherapy Products)별
  • 표적별
  • 작용기전별
  • 분자 종류별

치료제 개요

  • CEL-1000
    • 제품 개요
    • 작용기전
    • 연구개발(R&D) 진전 상황
  • Cell Therapy to Activate IL-10 for Autoimmune Myocarditis and Inflammation
  • Cellular Immunotherapy to Target Flt3L for Autoimmune Myocarditis
  • chagas disease vaccine
  • Drugs to Inhibit Alpha Myosin for Cardiovascular Disorders
  • OBR-5340
  • Small Molecule to Inhibit Coxsackievirus B3 3C Protease for Myocarditis

휴지 상태인 프로젝트

부록

도표

LSH 16.10.31

List of Tables

  • Number of Products under Development for Myocarditis, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Products under Development by Companies, H2 2018
  • Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Stage and Target, H2 2018
  • Number of Products by Stage and Mechanism of Action, H2 2018
  • Number of Products by Stage and Route of Administration, H2 2018
  • Number of Products by Stage and Molecule Type, H2 2018
  • Myocarditis - Pipeline by Apitope International NV, H2 2018
  • Myocarditis - Pipeline by CEL-SCI Corp, H2 2018
  • Myocarditis - Pipeline by Evotec AG, H2 2018
  • Myocarditis - Pipeline by Swedish Orphan Biovitrum AB, H2 2018
  • Myocarditis - Dormant Projects, H2 2018

List of Figures

  • Number of Products under Development for Myocarditis, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products by Top 10 Targets, H2 2018
  • Number of Products by Stage and Top 10 Targets, H2 2018
  • Number of Products by Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Routes of Administration, H2 2018
  • Number of Products by Stage and Routes of Administration, H2 2018
  • Number of Products by Molecule Types, H2 2018
  • Number of Products by Stage and Molecule Types, H2 2018

영문목차

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myocarditis - Pipeline Review, H2 2018, provides an overview of the Myocarditis (Cardiovascular) pipeline landscape.

Myocarditis is inflammation of the heart muscle. Myocarditis is an uncommon disorder that is usually caused by viral, bacterial, or fungal infections that reach the heart. Symptoms include chest pain, rapid or abnormal heartbeat, shortness of breath, at rest or during physical activity, fluid retention with swelling of legs, ankles and feet and fatigue. Treatment includes antibiotics, anti-inflammatory medicines to reduce swelling and diuretics to remove excess water from the body.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Myocarditis - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Myocarditis (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myocarditis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Myocarditis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Preclinical and Discovery stages are 1, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Myocarditis (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Myocarditis (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Myocarditis (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Myocarditis (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Myocarditis (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Myocarditis (Cardiovascular)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Myocarditis (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Myocarditis (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Myocarditis - Overview
    • Myocarditis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Myocarditis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Myocarditis - Companies Involved in Therapeutics Development
    • Apitope International NV
    • CEL-SCI Corp
    • Evotec AG
    • Swedish Orphan Biovitrum AB
  • Myocarditis - Drug Profiles
    • anakinra - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ATX-MYO - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CEL-1000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OBR-5340 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Peptides for Myocardial Infarction and Myocarditis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Coxsackievirus B3 3C Protease for Myocarditis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Myocarditis - Dormant Projects
  • Myocarditis - Product Development Milestones
    • Featured News & Press Releases
      • Dec 11, 2017: Evotec's Academic Bridge LAB282 with Oxford University celebrating one year of impact
      • Nov 10, 2016: Evotec and Oxford create novel Partnership called 'LAB282'
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer
Back to Top
아시아 최대 시장정보 제공
전세계에서 발행되고 있는 모든 시장조사보고서를
다루고 있습니다.
사이트에서 검색되지 않는 보고서도 문의 바랍니다.
 
La Merie Publishing
BCC Research